This content is from: Premium

Orbimed drug portfolio balances prognosis with prevention

Sam Isaly has the field covered.

By Pete GalloSometimes running a successful pharma and biotech hedge fund portfolio can be a practice in making a good prognosis about a company’s earnings potential. Other times it can be like preventive medicine, stopping fiscal folly before it starts. These days, Sam Isaly’s approach at Orbimed Healthcare Fund Management

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content